ReviewNutrients2017
Biomarkers to Monitor Gluten-Free Diet Compliance in Celiac Patients.
Review in Nutrients, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Pooled it
- Novel probiotic preparation withMicrobiology spectrum · 2024Trial
- Trial
- Parental perspectives on gluten immunogenic peptide urine testing in children with coeliac disease: a qualitative study on barriers, emotions and interest in point-of-care tools.BMJ open gastroenterology · 2026Article
- Factors associated with adherence to gluten-free diet in patients with concomitant celiac disease and type 1 diabetes.JPGN reports · 2026Article
- Correlation Between Non-Invasive Biomarkers and Histological Healing in Children with Celiac Disease: Role of Cytokines, Intestinal Fatty Acid-Binding Protein, and Tissue Transglutaminase Antibodies.Pediatric gastroenterology, hepatology & nutrition · 2026Article
- Testing for Faecal Gluten Immunogenic Peptides: Is It Useful to Evaluate Adherence to Gluten-Free Diet?Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Comparative Effectiveness of Urine vs. Stool Gluten Immunogenic Peptides Testing for Monitoring Gluten Intake in Coeliac Patients: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Impact of a Gluten-Free Diet in Adults With Celiac Disease: Nutritional Deficiencies and Challenges.Cureus · 2024Review
- Review
- Comparison of Self-Care Practices and BMI between Celiac and Non-Celiac Adolescent Populations.Healthcare (Basel, Switzerland) · 2024Article
- Article
- Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease.Nutrients · 2024Review
- Global Approach to Follow-Up of Celiac Disease.Foods (Basel, Switzerland) · 2024Review
- Gluten-Free Diet and Other Celiac Disease Therapies: Current Understanding and Emerging Strategies.Nutrients · 2024Review
- Predictors of slow responsiveness and partial mucosal recovery in adult patients with celiac disease.Gastroenterology and hepatology from bed to bench · 2023Article
- Replacing the Burden of the Gluten Free Diet: Then, Now, and the Future.International journal of molecular sciences · 2022Review
- Review article: Follow-up of coeliac disease.Alimentary pharmacology & therapeutics · 2022Review
- The global burden of coeliac disease: opportunities and challenges.Nature reviews. Gastroenterology & hepatology · 2022Review
- Spectroscopic investigation of faeces with surface-enhanced Raman scattering: a case study with coeliac patients on gluten-free diet.Analytical and bioanalytical chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gluten-free diet (GFD) is the only treatment for celiac disease (CD). There is a general consensus that strict GFD adherence in CD patients leads to full clinical and histological remission accompanied by improvement in quality of life and reduced long-term complications. Despite the importance of monitoring the GFD, there are no clear guidelines for assessing the outcome or for exploring its adherence. Available methods are insufficiently accurate to identify occasional gluten exposure that may cause intestinal mucosal damage. Serological tests are highly sensitive and specific for diagnosis, but do not predict recovery and are not useful for follow-up. The use of serial endoscopies, it is invasive and impractical for frequent monitoring, and dietary interview can be subjective. Therefore, the detection of gluten immunogenic peptides (GIP) in feces and urine have been proposed as new non-invasive biomarkers to detect gluten intake and verify GFD compliance in CD patients. These simple immunoassays in human samples could overcome some key unresolved scientific and clinical problems in CD management. It is a significant advance that opens up new possibilities for the clinicians to evaluate the CD treatment, GFD compliance, and improvement in the quality of life of CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.